Physician profile
Neha Sood
NPI 1447571567
$2,790.15
in general payments reported to CMS, 2019-2025
19 companies · $673 in 2025
The $673 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.22 · 2021: $125 · 2022: $111 · 2023: $508 · 2024: $1,287 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.18 | 2023-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $425.78 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $346.48 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Supernus Pharmaceuticals, INC. | $259.98 | 2023-2024 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $191.19 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $181.79 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Shield Therapeutics INC | $143.16 | 2023-2025 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $128.73 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $86.22 | 2019 | |
| Pfizer INC. | $76.71 | 2022-2025 | |
| Noven Therapeutics, LLC | $55.45 | 2023-2024 | Xelstrym |
| Phathom Pharmaceuticals, INC. | $43.51 | 2024-2025 | Voquezna |
| Lundbeck LLC | $39.96 | 2023-2024 | Rexulti, Brintellix |
| Phadia US INC. | $20.10 | 2024 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.55 | 2024 | Jardiance |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $16.52 | 2023 | Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $15.35 | 2025 | Zoryve |
| Exeltis, USA INC. | $13.89 | 2023 | Slynd |
| Exact Sciences Corporation | $13.60 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.